Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCP Regimen in Newly Diagnosed Multicentric Castleman's Disease
NCT03043105Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in multicentric Castleman disease (MCD), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
thalidomide
03
Conditions
multicentric Castleman disease (MCD)
Beyond the preview
Go deeper on NCT03043105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043105.